A drug-screening platform for ALS

A drug-screening platform for ALS
This shows a control iPSC-derived motor neuron (left) and a motor neuron derived from ALS patient-specific iPSC (right). Credit: Haruhisa Inoue's Laboratory, CiRA, Kyoto University

A research group at the Center for iPS Cell Research and Application (CiRA) at Japan's Kyoto University has successfully recapitulated amyotrophic lateral sclerosis (ALS)-associated abnormalities in motor neurons differentiated from induced pluripotent stem cells (iPSCs) obtained from patients with familial ALS, a late-onset, fatal disorder which is also known for Lou Gehrig's disease. In a drug screening assay using the disease model, the team further found that the chemical compound anacardic acid can rescue some ALS phenotypes in vitro.

In a study published online in Science Translational Medicine, Associate Professor Haruhisa Inoue and his team generated motor neurons from iPSCs derived from three ALS patients with mutations in Tar DNA-binding protein-43 (TDP-43). The motor neurons showed cellular phenotypes including vulnerability to stress, shorter neurites, and cytosolic aggregates similar to those seen in postmortem tissues from ALS patients. The team also found that TDP-43 mRNA was upregulated in the ALS motor neurons, which means that TDP-43 autoregulation was disturbed, and that TDP-43 protein in detergent-insoluble form aggregated with the splicing factor SNRPB2 in the nucleus, perturbing RNA metabolism. These findings shed light on the mechanism of disease onset.

Using the motor neurons as a , the researchers discovered that the anacardic acid can rescue the abnormal ALS motor neuron phenotypes. For example, when anacardic acid, a histone acetyltransferase inhibitor, was sprinkled on the motor neurons, TDP-43 was decreased, and the length of the increased.

''Our work represents an initial stage of drug screening for ALS using patient-specific iPSCs. TDP-43 is not only relevant to familial ALS but also to sporadic ALS, which represents the majority of ALS cases,'' said Inoue, a principal investigator at CiRA who is also one of research directors for the CREST research program funded by the Japan Science and Technology Agency. ''We will continue to work on ALS patient-specific iPSCs in order to help develop new drug seeds and candidates.''


Explore further

Disease progression halted in rat model of Lou Gehrig's disease

More information: Egawa et al. "Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells" Science Translational Medicine.
Journal information: Science Translational Medicine

Provided by Kyoto University
Citation: A drug-screening platform for ALS (2012, August 2) retrieved 24 January 2021 from https://medicalxpress.com/news/2012-08-drug-screening-platform-als.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments